Anti-pentraxin 3 antibodies and residual disease activity in rheumatoid arthritis
Authors' conclusion
Elevated anti-PTX3 antibodies in RA indicate residual active disease despite controlled inflammation.
Study context
- Population
- RA patients diagnosed per ACR/EULAR 2010 criteria
- Participants
- 83 patients
- Exposure
- Seronegative vs seropositive RA; RA vs historical PsA and FM controls
- Seropositive RAn = 42reference
- Seronegative RAn = 41
- Outcome
- Serum anti-PTX3 antibody levels and their associations with disease activity and PROMs
Methodological detailshistorical controls (PsA and FM), in-house ELISA
- Historical controls (PsA and FM)
- In-house ELISA
Main finding
As reported in the abstract
Serum anti-PTX3 antibody levels
- Seropositive RA vs PsA controls: P = 0.001
- Seropositive RA vs FM controls: P = 0.004
- Seronegative RA vs Seropositive RA: P = 0.032
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Anti-PTX3 levels: near-controlled RA (SJC28 ≤ 2, PtGA > 2) vs controlled disease (SJC28 ≤ 2, PtGA ≤ 2)Higher in near-controlled RA | P = 0.048 |
Correlation of anti-PTX3 antibodies with disease activity and patient-reported outcome measures (PROMs)
- CDAI, r
- 0.255
- PtGA, r
- 0.257
- VAS-GH, r
- −0.235
- VAS-pain, r
- 0.233
- HAQ, r
- 0.311
- No correlation with joint counts, inflammatory markers or physician's global assessment
PtGA association adjusted for BMI, SJC28, ESR and prednisone dosage
- β (P = 0.042)
- 0.206
Anti-PTX3 levels by treatment
- Lower with tocilizumab or abatacept vs TNFi or JAKi
Original publication
Anti-pentraxin 3 antibodies and residual disease activity in rheumatoid arthritis. Rheumatology (Oxford). Published 28 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →